Today we announced positive results from the pivotal Phase 3 study of investigational Orca-T versus conventional allogeneic stem cell transplant for the treatment of hematologic malignancies. The results will be presented at the 51st Annual Meeting of the EBMT on April 2, 2025.

We’re on the ground in Florence, Italy for the 51st Annual Meeting of the EBMT. Join us as we present results from the pivotal Phase 3 Precision-T study of Orca-T and other updates related to our lead investigational T-cell immunotherapy. bit.ly/4i8gp1p #EBMT25

This #AMLWorldAwarenessDay, we are bringing attention to the ~22,010 people who will be diagnosed with acute myeloid leukemia (#AML) in 2025 and patients who have already been living with this disease. If you have been diagnosed with AML, you are not alone in your treatment

Orca Bio’s Head of Global Market Access, Head of Business Development, and Head of Corporate Communications will be in San Diego this week for #FiercePharmaEngage.

May is National Cancer Research Month, a time to highlight the research that furthers our understanding of cancers to ultimately help the millions of people impacted. Hear from, Josie O’Shea, on the vital role research plays in advancing cancer science and medicine. #NCRM25

Orca Bio is pleased to announce the appointment of co-founder Nathaniel Fernhoff, Ph.D. as Chief Executive Officer. In addition, co-founder and Chief Operating Officer Jeroen Bekaert, Ph.D. has been appointed President. Read more here: bit.ly/3EZOiTI

On #ClinicalTrialsDay, we express our deepest gratitude to the patients who participate in clinical trials, & the researchers committed to saving & improving lives. Together, they help to further potentially life-saving clinical research & bring hope to countless others #CTD2025

On #WorldBloodCancerDay and every day, we are on a mission to transform the lives of patients and families affected by #bloodcancer through the development of our pipeline of high-precision cell therapies. #oncology #hematology #celltherapy

Welcome Andrea Blank to #TeamOrcaBio as VP of Medical Affairs! Andrea brings a wealth of strategic & clinical expertise in #celltherapy. At Orca Bio, she will be responsible for shaping our Medical Affairs strategy as we advance our pipeline of investigational cell therapies.

Orca Bio is thrilled to announce the appointment of Steve Gavel as Chief Commercial Officer and Allison Frisbee as SVP of Legal to support the company as it advances its pipeline of high-precision cell therapies. To read more: bit.ly/43ukckI

We're pleased to welcome Mike Hirschmann to #TeamOrcaBio as SVP of U.S. Commercial to lead the company’s U.S. commercial launch planning and execution! Mike brings 30+ years of biopharma experience at companies including Legend Biotech, Celgene and Puma Biotechnology.

Today, we commemorate #Juneteenth, the United States’ second Independence Day. At Orca Bio, we reflect on and celebrate this monumental day and significant milestone in the enduring fight for freedom. Join us in learning more: bit.ly/4k1vFx8

This month’s #EmployeeSpotlight is our Associate Medical Director, Renata Gilfanova, MD! Renata brings valuable clinical and operational expertise to #TeamOrcaBio, with a focus on cellular therapy and immune tolerance. As medical monitor for our Orca-T clinical programs, she has

The first half of 2025 was a defining chapter for Orca Bio. We shared the results of the pivotal Phase 3 study evaluating Orca-T, our lead investigational allogeneic T-cell immunotherapy, and announced the appointment of senior leaders as we advance toward commercialization.

Our CEO, Nathaniel Fernhoff recently joined Erin Harris on an episode of Cell&Gene: The Podcast to share more about Orca Bio’s journey – from foundational research to advancing our lead investigational cell therapy, and the path toward potential commercialization. Listen to

How to optimize cell and gene therapy commercialization remains a key goal of our industry. Who better to learn from than those who have been there before? Orca Bio’s CCO, Steve Gavel, will be speaking on a Reuters panel with Emily Chee, Daniel Grant and Rindy Dhillon to share

Orca Bio will present at the upcoming Society of Hematologic Oncology (SOHO) (SOHO) 2025 Annual Meeting. We look forward to sharing results from our Phase 3 Precision-T study of Orca-T, our lead investigational T-cell immunotherapy. #SOHO2025 #celltherapy #biotechnology #oncology #hematology

#TeamOrcaBio is now 250 employees and growing! We’re proud and grateful to have an incredible team of talented individuals working toward our mission of redefining the future of cell therapy and transforming care for patients with #bloodcancer. Interested in joining us?

Although all blood cancers have unique properties, they share a common need: research and innovation to further care for patients. This Blood Cancer Awareness Month, we join our partner Blood Cancer United in recognizing unmet needs across blood cancers and uniting for patients,

Last week, Team Orca Bio was on the ground in Houston, TX for the Society of Hematologic Oncology (SOHO) Annual Meeting to share positive results from the Phase 3 study of our investigational T-cell immunotherapy, Orca-T. #SOHO2025 #celltherapy #oncology #hematology